Vivos completes planned dosing schedule for feline sarcoma program
Vivos announced it has completed its planned dosing schedule to determine effectiveness of using the Company’s proprietary RadioGel™ therapy to treat feline sarcoma. The study results indicated RadioGel performed as designed, confirming OR without negative or detrimental side-effects. January 12, 2018